Marleen Keyaerts

13PUBLICATIONS
39CO-AUTHORS
Radiation therapyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 01, 2025
Immune modulation following α and β- radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model.

Hannelore Ceuppens, Kirsten De Ridder, Thomas Ertveldt

|Aug 26, 2023
Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [18F]FDG PET/CT Imaging and Clinical Features.

Ine Dirks, Marleen Keyaerts, Iris Dirven

|May 02, 2022
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.

Thomas Ertveldt, Lien De Beck, Kirsten De Ridder

|Nov 02, 2021
Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer.

Q Lecocq, P Debie, J Puttemans

|Oct 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.

Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts

|Jul 24, 2021
The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis.

Jens M Debacker, Odrade Gondry, Tony Lahoutte

Pageof 3

Frequent Collaborators

7 joint publications

Nick Devoogdt

6 joint publications

Karine Breckpot

5 joint publications

Quentin Lecocq

3 joint publications

Thomas Ertveldt